Abiraterone acetate and prednisone in the pre- and post-docetaxel setting for metastatic castration-resistant prostate cancer: a mono-institutional experience focused on cardiovascular events and their impact on clinical outcomes.
Ther Adv Med Oncol
; 10: 1758834017745819, 2018.
Article
en En
| MEDLINE
| ID: mdl-29383035
Texto completo:
1
Bases de datos:
MEDLINE
Tipo de estudio:
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Idioma:
En
Revista:
Ther Adv Med Oncol
Año:
2018
Tipo del documento:
Article
País de afiliación:
Italia